CONTENTS

CHICAGO POPULATION DATA

TRUMP-PHARMA-LIASON
CHICAGO POPULATION DATA

About 65 percent of African-American, Latino and Asian households in Chicago have so little savings and other assets that a sudden job loss, medical emergency or other income disruption would throw them into poverty within three months, according to a report on wealth inequities in the city. The median income of whites in Chicago is $70,960 compared with $56,373 for Asians, $41,188 for Latinos and $30,303 for blacks².

Population by Race

<table>
<thead>
<tr>
<th>Race</th>
<th>Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>9,177,877</td>
</tr>
<tr>
<td>African American</td>
<td>1,866,414</td>
</tr>
<tr>
<td>Asian</td>
<td>586,934</td>
</tr>
<tr>
<td>American Indian and Alaska Native</td>
<td>43,963</td>
</tr>
<tr>
<td>Native Hawaiian and Pacific Islander</td>
<td>4,050</td>
</tr>
</tbody>
</table>
TRUMP-PHARMA-LIAISON

If enacted, the Trump policies would result in up to 350,000 new jobs in the so-called Big Pharma over the next 10 years, according to PhRMA. This is a drop in the bucket because the employment in professional and business services added 522,000 jobs last year - just one year. The US economy added 156,000 jobs in one month - December 2016, which was short of expected 175,000 jobs; In the past 8 years, from January 2009, the US economy has added 11,250,000 people to total nonfarm payrolls.

Almost a decade (2000-2009), the pharmaceutical industry has cut 297,650 jobs by 2009, as many people as the total employment at the three largest drug makers -- Pfizer, Merck, and GlaxoSmithKline -- combined, according to consulting firm Challenger, Gray & Christmas report "A Decade In Drug Industry Layoffs".

The economy has added jobs for 75 straight months, the longest streak since 1939, although the overall rate of growth has been slower than in previous administrations. Between 2009 and 2013, US biopharma eliminated at least 156,000 American jobs, including scaling back R&D departments, slashing sales teams, and eliminating redundancies in post-merger workforces. Since then, the industry has continued to slice and dice sections of its employment base, particularly in the wake of a record level of M&A activity in the sector (there were 182 biopharma deals totaling $212 billion in 2014 alone). The U.S. economy has consistently created at least 100,000 jobs per month for the last three years, According to outplacement firm Challenger, Gray & Christmas, employers have announced 493,431 planned layoffs so far this year—that's a 36% increase from the same period last year and 2% more than the total number of layoffs announced in 2014. The Wall Street Journal points out that Pfizer, for example, has a habit of snapping up big companies and then chopping up jobs as it realizes synergies from those deals.

A Redistribution Of Talent And Resources: While company executives will always offer a good business rationale on the need for these consolidations, there is no doubt that biopharmaceutical researchers are aware that, on any given day, they could hear that their particular laboratory is going to be shuttered.
US-based employers announced 574,888 job cuts through November. That is 19 percent higher than the 2014 year-end total (483,171). At the current pace, 2015 is on track to be the biggest job cut year since 2009, when 1,272,030 job cuts were announced. Falling oil prices were blamed for 102,738 job cuts through November, which represents nearly one in every five job cuts announced in 2015. (Completing Pipeline Projects will certainly exacerbate the situation by contributing to the oil price fall, which is responsible for 0.1 million jobs lost. Once the pipelines are completed, additional construction and related workers will be laid off, further contributing to the job loss).5

Since 2010, R&D investment in the industry has been relatively flat, rising less just about $500 million over that timeframe (2010-2015). Pfizer, having absorbed 134,000 jobs through acquiring Warner-Lambert, Pharmacia, and Wyeth during the 1999-2009 period, saw its overall employment grow by roughly 27,000 by the end of 2013—in effect, disappearing over 100,000 jobs between 1999 and 2013.

- In Drug Mergers, There's One Sure Bet: The Layoffs.
- Big Pharma Just Had a Terrible, Horrible, No Good, Very Bad Week of Job Cuts.
- Counterfeit of medicines causes 37,000 job losses in EU Pharma Industry. New Case of Counterfeits Suspected at German Company.
REFERENCES AND NOTES


   https://www.linkedin.com/in/dedrick-asante-muhammad-9966525
   http://www.huffingtonpost.com/author/dedrick-muhammad

Chicago city, IL: 2,695,598; http://www.census.gov/2010census/popmap/index.php

3 A Decade In Drug Industry Layoffs

4 The Silver Lining In Big Pharma Layoffs And Site Closures? A Redistribution Of Talent And Resources:

Biopharma’s new normal: Constant makeovers leave R&D jobs at permanent risk:

5 2016 Employment Outlook.pdf

6 In addition to the primary sources cited above, additional references include: http://www.healthcentral.com/chronic-pain/c/5949/135331/fibromyalgia/

Disclaimer All information is intended for your general knowledge only and is not a substitute for medical advice or treatment for special medical conditions or any specific health issues or starting a new fitness regimen.

“Where the mind is without fear and the head is held high, Where knowledge is free Where the world has not been broken up into fragments, By narrow domestic walls.” Rabindranath Tagore (1861-1941), Gitanjali, 1912.

One World One Family

AUM! SWASTI!

Om! Asatoma Sadgamaya, Tamasoma Jyotirgamaya, Mrityorma Amritamgamaya, Om Shantih, Shantih, Shantih! (Aum! Lead the world from wrong path to the right path, from ignorance to knowledge, from mortality to immortality, and peace!)

SWASTI! AUM!